[{"id":"4c2fc1fb-e66a-4255-b1b5-1f24873e7431","acronym":"","url":"https://clinicaltrials.gov/study/NCT03974217","created_at":"2021-01-18T19:32:53.912Z","updated_at":"2024-07-02T16:35:44.626Z","phase":"Phase 1","brief_title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","source_id_and_acronym":"NCT03974217","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TMB • FLT3 • IDH1 • IDH2 • STAG2 • RAD21 • SMC1A • SMC3","pipe":" | ","alterations":" STAG2 mutation","tags":["TMB • FLT3 • IDH1 • IDH2 • STAG2 • RAD21 • SMC1A • SMC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • decitabine • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-06-27"}]